Celltrion Healthcare Gears Up For Infliximab SC Launch

UK Commercial Head Reveals Strategy For Innovative Biosimilar Infliximab

 
• By Dave Wallace

As Celltrion Healthcare prepares to roll out Remsima SC, its subcutaneous infliximab, in Europe – starting in the UK and Germany – Celltrion Healthcare’s UK commercial head, Matthew Eddleston, speaks to Generics Bulletin about how the innovative biosimilar will be positioned in the market.

Innovation_Button
Highlighting Remsima (infliximab) SC’s innovative aspects will be at the heart of Celltrion Healthcare’s strategy • Source: Shutterstock

More from Biosimilars

More from Products